Loss of 5α-Reductase Type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice

Endocrinology

Volumn 154, Issue 12, 2013, Pages 4536-4547

  Dowman, Joanna K ^a,b   Hopkins, Laurence J ^a   Reynolds, Gary M ^a   Armstrong, Matthew J ^a,b   Nasiri, Maryam ^a   Nikolaou, Nikolaos ^a   Van Houten, E Leonie A F ^c   Visser, Jenny A ^c   Morgan, Stuart A ^a   Lavery, Gareth G ^a   Oprescu, Andrei ^a   Hübscher, Stefan G ^a,b   Newsome, Philip N ^a,b   Tomlinson, Jeremy W ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FATTY ACID; GLUCOCORTICOID; INSULIN; MESSENGER RNA; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; TRIACYLGLYCEROL; BOLDENONE; CORTICOSTERONE; FAT INTAKE; ISOPROTEIN; STEROID 5ALPHA REDUCTASE; TESTOSTERONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET; DISEASE COURSE; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; GLUCOSE TOLERANCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER INJURY; LIVER PROTECTION; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CELL LINE; CLASSIFICATION; ENZYMOLOGY; FAT INTAKE; FATTY LIVER; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LIVER; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TOXICITY;

3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE; CORTICOSTERONE; DIETARY FATS; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PROTEIN ISOFORMS; TESTOSTERONE;

EID: 84888231367     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1592     Document Type: Article

References (52)

1. Bugianesi E. Review article: steatosis, the metabolic syndrome and cancer. Aliment Pharmacol Ther. 2005;22(Suppl 2):40-43.
2. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 2002;36:1349-1354.
3. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
4. Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140:124-131.
5. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology. 2005;129:375-378.
6. Angulo P. Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology. 2010;51:373-375.
7. Ekstedt M, Franzén LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865-873.
8. Dowman JK, Hopkins LJ, Armstrong MJ, et al. 5α-Reductase-1 knockout protects against hepatocarcinogenesis in a murine model of NASH [abstract]. J Hepatol. 2012;56(Suppl 2):S488-S489.
9. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab. 2011;13:692-702.
10. Rockall AG, Sohaib SA, Evans D, et al. Hepatic steatosis in Cushing's syndrome: a radiological assessment using computed tomography. Eur J Endocrinol. 2003;149:543-548.
11. Gabbi C, Carubbi F, Losi L, et al. Nonalcoholic fatty liver disease induced by leuprorelin acetate. J Clin Gastroenterol. 2008;42:107-110.
12. Kim S, Kwon H, Park JH, et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012;12:69.
13. Völzke H, Aumann N, Krebs A, et al. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men. Int J Androl. 2010;33:45-53.
14. Andersson S, Russell DW. Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci U S A. 1990;87:3640-3644.
15. Russell DW, Wilson JD. Steroid 5 α-reductase: two genes/two enzymes. Annu Rev Biochem. 1994;63:25-61.
16. Cantagrel V, Lefeber DJ, Ng BG, et al. SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell. 2010;142:203-217.
17. Berra M, Williams EL, Muroni B, et al. Recognition of 5α-reductase-2 deficiency in an adult female 46XY DSD clinic. Eur J Endocrinol. 2011;164:1019-1025.
18. Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11β-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5α-reductase activity. Diabetes. 2008;57:2652-2660.
19. Baudrand R, Domínguez JM, Carvajal CA, et alE. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients. Metabolism. 2011;60:1775-1780.
20. Konopelska S, Kienitz T, Hughes B, et al. Hepatic 11β-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf). 2009;70:554-560.
21. Tetri LH, Basaranoglu M, Brunt EM, Yerian LM, Neuschwander-Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol. 2008;295:G987-G995.
22. Lê KA, Ith M, Kreis R, et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr. 2009;89:1760-1765.
23. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48:993-999.
24. Koppe SW, Elias M, Moseley RH, Green RM. Trans fat feeding results in higher serum alanine aminotransferase and increased insulin resistance compared with a standard murine high-fat diet. Am J Physiol Gastrointest Liver Physiol. 2009;297:G378-G384.
25. Dowman JK, Hopkins LJ, Reynolds GM, et al. Chronic metabolic-induced liver injury, hepaic stem cell activation and hepatocellular carcinoma in a murine obesity model [abstract]. Gut. 2012;61(Suppl 3):A23.
26. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
27. Morgan SA, Gathercole LL, Simonet C, et al. Regulation of lipid metabolism by glucocorticoids and 11β-HSD1 in skeletal muscle. Endocrinology. 2013;154:2374-2384.
28. van Houten EL, Kramer P, McLuskey A, Karels B, Themmen AP, Visser JA. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology. 2012;153:2861-2869.
29. Jamdar SC. Glycerolipid biosynthesis in rat adipose tissue. Influence of adipose-cell size and site of adipose tissue on triacylglycerol formation in lean and obese rats. Biochem J. 1978;170:153-160.
30. Ahmed A, Rabbitt E, Brady T, et al. A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLoS ONE. 2012;7:e29531.
31. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829-838.
32. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002;23:201-229.
33. Amatruda JM, Danahy SA, Chang CL. The effects of glucocorticoids on insulin-stimulated lipogenesis in primary cultures of rat hepatocytes. Biochem J. 1983;212:135-141.
34. Mangiapane EH, Brindley DN. Effects of dexamethasone and insulin on the synthesis of triacylglycerols and phosphatidylcholine and the secretion of very-low-density lipoproteins and lysophosphatidylcholine by monolayer cultures of rat hepatocytes. Biochem J. 1986;233:151-160.
35. Lemke U, Krones-Herzig A, Berriel Diaz M, et al. The glucocorticoid receptor controls hepatic dyslipidemia through Hes1. Cell Metab. 2008;8:212-223.
36. D'souza AM, Beaudry JL, Szigiato AA, et al. Consumption of a high-fat diet rapidly exacerbates the development of fatty liver disease that occurs with chronically elevated glucocorticoids. Am J Physiol Gastrointest Liver Physiol. 2012;302:G850-G863.
37. Mahendroo MS, Cala KM, Hess DL, Russell DW. Unexpected virilization in male mice lacking steroid 5α-reductase enzymes. Endocrinology. 2001;142:4652-4662.
38. Windahl SH, Andersson N, Borjesson AE, et al. Reduced bone mass and muscle strength in male 5α-reductase type 1 inactivated mice. PLoS ONE. 2011;6:e21402.
39. Lin HY, Yu IC, Wang RS, et al. Increased hepatic steatosis and insulin resistance in mice lacking hepatic androgen receptor. Hepatology. 2008;47:1924-1935.
40. Corcoran MP, Meydani M, Lichtenstein AH, Schaefer EJ, Dillard A, Lamon-Fava S. Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women. J Endocrinol. 2010;206:217-224.
41. González F, Nair KS, Daniels JK, Basal E, Schimke JM. Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am J Physiol Endocrinol Metab. 2012;302:E297-E306.
42. Vignozzi L, Cellai I, Santi R, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214:31-43.
43. Vignozzi L, Morelli A, Sarchielli E, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J Endocrinol. 2012;212:71-84.
44. Xu J, Itoh Y, Hayashi H, Takii T, Miyazawa K, Onozaki K. Dihydrotestosterone inhibits interleukin-1α or tumor necrosis factor α-induced proinflammatory cytokine production via androgen receptor-dependent inhibition of nuclear factor-κB activation in rheumatoid fibroblast-like synovial cell line. Biol Pharm Bull. 2011;34:1724-1730.
45. Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-2443.
46. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78(Suppl 1):172-179.
47. Iqbal MJ, Wilkinson ML, Forbes A, Corbishley TP, Williams R. Preponderance of serum and intra-hepatic 5α-dihydrotestosterone in males with hepatocellular carcinoma despite low circulating androgen levels. J Hepatol. 1986;3:304-309.
48. Yu L, Nagasue N, Makino Y, Nakamura T. Effect of androgens and their manipulation on cell growth and androgen receptor (AR) levels in AR-positive and -negative human hepatocellular carcinomas. J Hepatol. 1995;22:295-302.
49. Forbes A, Wilkinson ML, Iqbal MJ, Johnson PJ, Williams R. Response to cyproterone acetate treatment in primary hepatocellular carcinoma is related to fall in free 5α-dihydrotestosterone. Eur J Cancer Clin Oncol. 1987;23:1659-1664.
50. Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985;89:643-647.
51. Ohnishi S, Murakami T, Moriyama T, Mitamura K, Imawari M. Androgen and estrogen receptors in hepatocellular carcinoma and in the surrounding noncancerous liver tissue. Hepatology. 1986;6:440-443.
52. Maruyama S, Nagasue N, Dhar DK, et al. Preventive effect of FK143, a 5α-reductase inhibitor, on chemical hepatocarcinogenesis in rats. Clin Cancer Res. 2001;7:2096-2104.